Introduction
Cardiovascular disease is one of the most frequent diseases many Americans suffer from and one of the most evident reasons of death among people under 20. Therefore, it seems to be necessary to take the steps, prevent the development of this disease, and help people resist the challenges caused by CVD (George, Tong, Sonnenfeld, & Hong, 2012). The current paper aims at discussing the peculiarities of one of the existing guidelines for CVD prevention in clinical practices, the use of aspirin in clinical practices, and discussing this recommendation’s connection to the determinants of health actions.
Origins
The risk for cardiovascular problems has been considerably increased during the last decade. People want to have a good and stable assistance and hope to decrease risk with the help of some medications. In 2007, the representatives of the American Diabetes Association and the American Heart Association introduced aspirin therapy as an option for primary prevention for people over 40, who are challenged by such risks like smoking, hypertension, family history, etc. (Pignone, Alberts, Colwell, Cushman, Inzucchi, & Roseson, 2010). During a certain period of time, the effects of aspirin have been thoroughly studied. It has been proved that aspirin promotes the decrease of cardiovascular morbidity and even mortality cases (Ittaman, VanWormer, & Rezkalla, 2014).
Contributions to the Development
Recently, the US Preventive Services Task Force has updated the information and described how aspirin should be used by men aged 45-79, women 55-79, men under 45, women under 55, and both, males and females, above 80 (Agency for Healthcare Research and Quality, 2011). It is recommended to use a daily low-dose of aspirin to prevent heart attack risks only after consulting a personal physician because the benefits and risks of aspirin use are different for each person (American Heart Association, 2015).
Current Conditions
Nowadays, many people continue using this preventive strategy as one of the safest and the easiest ways to rely on. However, the current changes within the guidelines show that it is not effective for people above 80 to use this therapy. There are no particular recommendations to consider. It is also not suggested for men under 45 and women under 55 to use aspirin frequently as it is not effective if no additional risks factors are identified. Still, men age 45-79 years, and women age 55-79 years are encouraged to use aspirin when potential CVD benefits overwhelm potential harm (Agency for Healthcare Research and Quality, 2011).
Relation to the Determinants of Health
In fact, the use of aspirin does not have a close connection or impact on such determinants of health like lifestyle, social relationships, the environment, etc. However, the reason of why aspirin should be used by people (to prevent CVD) is closely connected to the style of life chosen by people, the necessity to choose an appropriate environment, and the choice of healthcare services because CVD is one of the chronic disease that causes death among people of different age (Green, Tones, Cross, & Woodall, 2015). Therefore, when people decide to use aspirin and get a chance to prevent their possible heart problems, they make a right decision and have enough explanations to support their choice.
Conclusion
In general, the guideline to use aspirin to prevent CVD in clinical practices is not a new idea. Still, not many people are aware of it and want to consult their own therapists to be sure of the correctness of their choice. There are many ways to prevent risk, and aspirin therapy is probably one of the safest for people between 45 and 80.
References
Agency for Healthcare Research and Quality. (2011). Aspirin for the prevention of cardiovascular disease. Web.
American Heart Association. (2015). Aspirin and heart disease. Web.
George, M.G., Tong, X., Sonnenfeld, N., & Hong, Y. (2012). Recommended use of aspirin and other antiplatelet medications among adults – national ambulatory medical care survey and national hospital ambulatory medical care survey, United States, 2005-2008. Morbidity and Mortality Weekly Report, 61(2), 11-18.
Green, J., Tones, K., Cross, R., & Woodall, J. (2015). Health promotion: Planning strategies. Thousand Oaks, CA: Sage.
Ittaman, S.V., VanWormer, J.J., & Rezkalla, S.H. (2014). The role of aspirin in the prevention of cardiovascular disease. Clinical Medicine & Research, 12(3-4), 147-154.
Pignone, M., Alberts, M.J., Colwell, J.A., Cushman, M., Inzucchi, S.E. & Roseson, R.S. (2010). Aspirin for primary prevention of cardiovascular events in people with diabetes: A position statement of the American diabetes association, a scientific statement of the American heart association, and an expert consensus document of the American college of cardiology foundation. Diabetes Care, 33(6), 1395-1402.